About 19 results found for searched term "TNF Receptor" (0.155 seconds)
| Cat.No. | Name | Target |
|---|---|---|
| M2448 | GANT61 | Gli |
| NSC 136476 | ||
| GANT61 is a Gli1 and Gli2 inhibitor targeting the Hedgehog/GLi pathway that inhibits GLI1- and GLI2-induced transcription with an IC50 of 5 μM. In addition, GANT61 selectively acts on the transcription of other pathways such as TNF and glucocorticoid receptor genes. | ||
| M1545 | Infliximab | TNF Receptor |
| Remicade; Avakine; CT-P13 | ||
| Infliximab is a purified, recombinant DNA-derived chimeric human-mouse IgG monoclonal antibody that blocks TNF-α interaction with TNF-α receptor 1 (TNFR1) and TNFR2. For the treatment of autoimmune diseases. Infliximab is available in BALB/ C or C57/Bl6 mice. | ||
| M6224 | Etanercept | TNF Receptor |
| Etanercept is a dimer fusion protein that binds tumor necrosis factor (TNF) as a TNF inhibitor. Etanercept competitively inhibits the binding of TNF-α and TNF-β to TNF receptors on the cell surface, rendering tumor necrosis factor biologically inactive. | ||
| M8516 | R-7050 | TNF Receptor |
| TNF-α Antagonist III; R7050 | ||
| R-7050 is a cell-permeable TNF-α receptor antagonist that blocks TNF-α-induced binding of TNF-αRI with TNFαR-associated death domain protein and receptor interacting protein 1, blocking internalization of the TNFα-TNFαR complex. | ||
| M10842 | KAG-308 | Prostaglandin Receptor |
| KAG-308 is an effective, selective, orallyable EP4 receptor (a subtype of prostaglandin E2 receptor) agonist that inhibits colitis, promotes tissue mucosal healing, and effectively inhibits the production of TNF-α. KAG-308 for human EP4 receptors Ki value and EC50 The values were 2.57 nM and 17 nM, respectively, which were more selective than EP1, EP2, EP3, and IP receptors. | ||
| M10950 | SPD304 | Others |
| SPD304 is a selective inhibitor of tumor necrosis factor α (TNF-α) that promotes the separation of tumor necrosis factor trimers, thereby blocking their interaction with receptors. SPD304 inhibits tumor necrosis factor in vitro α and receptor 1 binding IC50 The value is 22 μM. | ||
| M11390 | Recombinant Human 4-1BB Protein (HEK293) | Recombinant Proteins |
| TNFRSF9、4-1BB、CD137、CDw137、ILA | ||
| Recombinant Human 4-1BB Protein (HEK293) Protein sequence: DNA sequence encoding human 4-1BB (UniProtKB/ Swiss-PROt: Q07011.1) expressed with His tag at the C-terminal Bioactivity: 4-1BB, also known as CD137, is a member of the tumor necrosis factor receptor superfamily 9 (TNFRSF9) induced by lymphocyte activation (ILA), and is a costimulatory molecule of the tumor necrosis factor receptor superfamily. | ||
| M21686 | Recombinant Mouse BAFF (Mammalian, N-mFc) | Recombinant Proteins |
| TNF Ligand Superfamily Member 13B; B-cell-activating factor | ||
| Recombinant Mouse BAFF (TNFSF13B/TNFSF20) belongs to the tumor necrosis factor family. TNFSF13/APRIL binds to the same 2 receptors. Together, they form a 2 ligands -2 receptors pathway involved in the stimulation of B- and T-cell function and the regulation of humoral immunity. The target gene encoding Ala127-Leu309 is expressed with a mFc tag at the N-terminus. | ||
| M24544 | Enavatuzumab | TNF Receptor |
| PDL192; ABT-361 | ||
| Enavatuzumab (PDL192; ABT-361) is a humanized IgG1 monoclonal antibody targeting the receptor of TNF-like weak inducer of apoptosis (TWEAK). TWEAK (Fn14; TNFRSF12A), the natural ligand of the TWEAK receptor (TweakR), stimulates multiple cellular responses. Enavatuzumab induces tumor growth inhibition through direct TweakR signaling and antibody dependent cell-mediated cytotoxicity (ADCC). Enavatuzumab can actively recruits and activates myeloid effectors to kill tumor cells. | ||
| M24717 | Lenercept | TNF Receptor |
| p55TNF-R:Ig Ro 45-2081; TNFR55-IgG1 | ||
| Lenercept (Ro 45-2081) is a recombinant fusion protein that consists of the soluble TNF-receptor (p55) linked to the Fc portion of human IgG1. | ||
| M24760 | Tavolixizumab | Others |
| MEDI 0562; Tavolimab | ||
| Tavolixizumab (MEDI 0562; Tavolimab) is a human monoclonal antibody to TNFRSF4 (TNF receptor superfamily member 4) for use in cancer immunology research. | ||
| M24932 | Ivuxolimab | Others |
| Ivuxolimab is an OX40 (also known as CD134; TNFRSF4) agonist monoclonal antibody. OX40 is a costimulatory receptor expressed on activated CD4+ and CD8+ T cells. Ivuxolimab shows antitumor activity, with potential immunostimulatory activity. | ||
| M24986 | Ruplizumab | TNF Receptor |
| BG 9588; Anti-Human CD40L Recombinant Antibody | ||
| Ruplizumab (BG 9588) is a humanized monoclonal anti-CD40L (TNF Receptor) IgG1κ antibody. Ruplizumab has the potential for systemic lupus erythematosus disease research. | ||
| M25015 | Revdofilimab | OX Receptor |
| ABBV-368 | ||
| Revdofilimab (ABBV-368) is a human IgG1 agonist monoclonal antibody against OX40. Among them, OX40 is a member of the TNF receptor superfamily expressed on activated and memory T cell subsets and T regulatory cells. | ||
| M25139 | Atibuclimab | Others |
| Atibuclimab, is a chimeric monoclonal antibody directed against CD14 and is composed of murine variable and human IgG4 Fc regions. Atibuclimab can be used for the research of amyotrophic lateral sclerosis. Atibuclimab attenuates LPS-induced symptoms and strongly inhibits LPS-induced proinflammatory cytokine release, while only delaying the release of the anti-inflammatory cytokines soluble TNF receptor type I and IL-1 receptor antagonist. | ||
| M27716 | SPD304 dihydrochloride | TNF Receptor |
| SPD304 dihydrochloride is a selective TNF-α inhibitor, which promotes dissociation of TNF trimers and therefore blocks the interaction of TNF and its receptor. SPD304 has an IC50 of 22 µM for inhibiting in vitro TNF receptor 1 (TNFR1) binding to TNF-α. | ||
| M27810 | NecroX-7 | HMGB1 |
| NecroX-7 is a potent free radical scavenger and a HMGB1 (high-mobility group box 1) inhibitor. NecroX-7 can be used as an antidote to acetaminophen toxicity. NecroX-7 exerts a protective effect by preventing the release of HMGB1 in ischemia/reperfusion injury. NecroX-7 inhibits the HMGB1-induced release of TNF and IL-6, as well as the expression of TLR-4 and receptor for advanced glycation end products. NecroX-7 can be used graft-versus-host disease (GVHD) research. | ||
| M43957 | Recombinant Human TNF RII (Mammalian, C-6His) | Recombinant Proteins |
| Tumor Necrosis Factor Receptor II; TNFRSF1B | ||
| Recombinant Human TNF RII belongs to the TNFR (tumor necrosis factor receptor) superfamily characterized by cysteine-rich extracellular domains. TNFRII is strongly expressed at the cartilage-pannus junction, and plays a major role in a subset of families with multiple cases of rheumatoid arthritis (RA). | ||
| M45267 | Recombinant Mouse Fas/CD95 Protein (Mammalian, C-6His) | Recombinant Proteins |
| Apoptosis-mediating surface antigen FAS; TNFRSF6 | ||
| Mouse Apoptosis-mediating surface antigen FAS (Fas) belongs to the death receptor subfamily of the TNF receptor superfamily. FAS-mediated apoptosis may have a role in the induction of peripheral tolerance, in the antigen-stimulated suicide of mature T-cells, or both. | ||
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.
